Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open Label Study Designed to Evaluate the Safety and Efficacy of a 1% Topical Formulation of KM-001 in the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenital Diseases

NCT05435638 is registered in ClinicalTrials.gov with Orvida Pharma (formerly Kamari Pharma) as lead sponsor.

NCT NCT05435638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05435638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open Label Study Designed to Evaluate the Safety and Efficacy of a 1% Topical Formulation of KM-001 in the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenital Diseases
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Phase
Phase 1
Overall status
Completed
Start date
July 17, 2022
Completion date
September 5, 2024
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pachyonychia congenita, punctate palmoplantar keratoderma type 1